Rep. Burgess Discourages Government Intervention On Paying For Cures
”You may not like what we figure out,” so “I encourage you to do it first,” he tells health care stakeholders.
You may also be interested in...
Trump’s ideas for curbing drug pricing have support in Congress but not among those in power; Republican leaders, including the president-elect’s choice for HHS secretary, Tom Price, have long opposed government negotiation in Medicare.
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.